{
  "first_published_at": "2011-05-11", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON117322", 
  "title": "Prasugrel (Efient▼): rare but serious hypersensitivity reactions", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Secondary care\", \"Primary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 154, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Prasugrel (Efient&#9660;): rare but serious hypersensitivity reactions</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: May 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Prasugrel (Efient&#9660;) has been rarely associated with reports of serious hypersensitivity reactions including, very rarely, angioedema; some of which occurred in patients with a history of hypersensitivity to clopidogrel. Healthcare professionals should be aware of this risk when prescribing prasugrel<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Prasugrel is a thienopyridine, belonging to the same class of medicines as clopidogrel, and acts as an inhibitor of platelet activation and aggregation.</p><p>Coadministered with aspirin, prasugrel is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ie, unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction) undergoing percutaneous coronary intervention.</p><p>Further safety information has recently been identified from postmarketing case reports describing serious hypersensitivity reactions including, very rarely, angioedema. As at April 2011, nine such cases have been reported worldwide in association with use in approximately 727 000 patients. Some cases have occurred in patients with a known history of hypersensitivity to clopidogrel, but others have no history of clopidogrel exposure. At present, the mechanism for these allergic reactions is unclear. The time to onset of symptoms ranged from immediately after treatment to up to 5&ndash;10 days later.&nbsp;&nbsp;</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>prescribers should be aware of the potential risk of rare but serious hypersensitivity reactions with prasugrel and should monitor for signs in all patients, including those with a previous known history of hypersensitivity reactions to thienopyridines</li>\r\n\t\t\t\t<li>when prescribing prasugrel, inform patients of the potential risk of hypersensitivity reactions, including angioedema</li>\r\n\t\t\t\t<li>suspected adverse reactions to prasugrel should be reported via the <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a>&nbsp;<br>    &nbsp;</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Advice for patients taking prasugrel:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>patients should inform their doctor immediately if they experience symptoms suggesting hypersensitivity or allergic reaction (eg, swelling of the face, neck, tongue, lips, or throat; rash; itching; or shortness of breath)</li>\r\n\t\t\t</ul></div><p><br><strong>Further information:</strong></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263\">letter for healthcare professionals sent April 2011</a></p><p>BNF section <a href=\"http://bnf.org/bnf/bnf/61/202499.htm?q=prasugrel&t=search&ss=text&p=1\" target=\"_blank\">2.9 Antiplatelet drugs</a><br></p><p><em>Article citation: Drug Safety Update May 2011 vol 4 issue 10: A1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Prasugrel is a thienopyridine, belonging to the same class of medicines as clopidogrel, and acts as an inhibitor of platelet activation and aggregation.</p><p>Coadministered with aspirin, prasugrel is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ie, unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction) undergoing percutaneous coronary intervention.</p><p>Further safety information has recently been identified from postmarketing case reports describing serious hypersensitivity reactions including, very rarely, angioedema. As at April 2011, nine such cases have been reported worldwide in association with use in approximately 727 000 patients. Some cases have occurred in patients with a known history of hypersensitivity to clopidogrel, but others have no history of clopidogrel exposure. At present, the mechanism for these allergic reactions is unclear. The time to onset of symptoms ranged from immediately after treatment to up to 5&#8211;10 days later.&#160;&#160;</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>prescribers should be aware of the potential risk of rare but serious hypersensitivity reactions with prasugrel and should monitor for signs in all patients, including those with a previous known history of hypersensitivity reactions to thienopyridines</li>\r\n\t\t\t\t<li>when prescribing prasugrel, inform patients of the potential risk of hypersensitivity reactions, including angioedema</li>\r\n\t\t\t\t<li>suspected adverse reactions to prasugrel should be reported via the <a href=\"http://www.yellowcard.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a>&#160;<br>    &#160;</li>\r\n\t\t\t</ul>\r\n\t\t\t<p><strong>Advice for patients taking prasugrel:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>patients should inform their doctor immediately if they experience symptoms suggesting hypersensitivity or allergic reaction (eg, swelling of the face, neck, tongue, lips, or throat; rash; itching; or shortness of breath)</li>\r\n\t\t\t</ul></div><p><br><strong>Further information:</strong></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263\">letter for healthcare professionals sent April 2011</a></p><p>BNF section <a href=\"http://bnf.org/bnf/bnf/61/202499.htm?q=prasugrel&amp;t=search&amp;ss=text&amp;p=1\" target=\"_blank\">2.9 Antiplatelet drugs</a><br></p><p><em>Article citation: Drug Safety Update May 2011 vol 4 issue 10: A1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-05-01", 
  "date_last_modified": "2011-05-10", 
  "_assets": [], 
  "_item_id": 154, 
  "summary": "Prasugrel (Efient▼) has been rarely associated with reports of serious hypersensitivity reactions including, very rarely, angioedema; some of which occurred in patients with a history of hypersensitivity to clopidogrel. Healthcare professionals should be aware of this risk when prescribing prasugrel", 
  "body": "Article date: May 2011\n\nPrasugrel is a thienopyridine, belonging to the same class of medicines as clopidogrel, and acts as an inhibitor of platelet activation and aggregation.\n\nCoadministered with aspirin, prasugrel is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ie, unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction) undergoing percutaneous coronary intervention.\n\nFurther safety information has recently been identified from postmarketing case reports describing serious hypersensitivity reactions including, very rarely, angioedema. As at April 2011, nine such cases have been reported worldwide in association with use in approximately 727 000 patients. Some cases have occurred in patients with a known history of hypersensitivity to clopidogrel, but others have no history of clopidogrel exposure. At present, the mechanism for these allergic reactions is unclear. The time to onset of symptoms ranged from immediately after treatment to up to 5–10 days later.  \n\nAdvice for healthcare professionals:  \n  \n  * prescribers should be aware of the potential risk of rare but serious hypersensitivity reactions with prasugrel and should monitor for signs in all patients, including those with a previous known history of hypersensitivity reactions to thienopyridines  \n  * when prescribing prasugrel, inform patients of the potential risk of hypersensitivity reactions, including angioedema  \n  * suspected adverse reactions to prasugrel should be reported via the [Yellow Card Scheme](http://www.yellowcard.gov.uk/)   \n   \n  \nAdvice for patients taking prasugrel:  \n  \n  * patients should inform their doctor immediately if they experience symptoms suggesting hypersensitivity or allergic reaction (eg, swelling of the face, neck, tongue, lips, or throat; rash; itching; or shortness of breath)  \n  \n  \nFurther information:\n\nSee [letter for healthcare professionals sent April 2011](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON117263)\n\nBNF section [2.9 Antiplatelet drugs](http://bnf.org/bnf/bnf/61/202499.htm?q=prasugrel&t=search&ss=text&p=1)  \n\n\nArticle citation: Drug Safety Update May 2011 vol 4 issue 10: A1.\n"
}